Inherited Liver Diseases

• Audio chapter
  Single-voice audio, listen on the commute.
• ABIM-format MCQs
  5-option vignettes with full wrong-answer teaching.
• Study guide
  Tables, decision trees, primary sources.
• AI tutor
  Chapter-grounded, answers the question you're stuck on.

What this chapter covers

• Section 22.1: Hereditary hemochromatosis iron metabolism, genetics, and penetrance

  Hereditary hemochromatosis iron overload is driven by inappropriately low hepcidin signaling, which removes the brake on enterocyte ferroportin and accelerates dietary iron absorption.

• Section 22.2: HH diagnosis, phlebotomy, and HCC surveillance

  The diagnostic gate (ACG 2019, with EASL 2022 endorsing the same two-tier framework) requires fasting transferrin saturation at least 45 percent in men or 40 percent in women plus elevated ferritin (over 300 ng per mL in men or 200 ng per mL in women); HFE genotyping confirms C282Y homozygosity.

• Section 22.3: Wilson disease diagnosis and Leipzig score

  Wilson disease (ATP7B on chromosome 13q14.3, with over 500 mutations described and approximately 380 disease-associated; H1069Q is the most common variant in European descent at 15 to 25 percent prevalence) impairs biliary copper excretion and ceruloplasmin loading.

• Section 22.4: Wilson treatment, pregnancy, and monitoring

  First-line chelation in symptomatic Wilson is trientine, paired with zinc for maintenance and counseling on a low-copper diet (avoid shellfish, organ meats, nuts, chocolate, mushrooms).

• Section 22.5: Alpha-1 antitrypsin deficiency

  PiZZ alpha-1 antitrypsin deficiency causes both pulmonary disease (early-onset panacinar emphysema, lower-lobe predominant in non-smokers) and hepatic disease (chronic hepatitis to cirrhosis).

• Section 22.6: Cystic fibrosis-associated liver disease

  Cystic fibrosis affects approximately 1 in 3,000 live births in the United States and Northern Europe, and CF-associated liver disease (CFLD) develops in 5 to 10 percent of CF patients over time.

• Section 22.7: Polycystic liver disease

  Polycystic liver disease in the autosomal dominant polycystic kidney disease (ADPKD) context accompanies kidney cysts; ADPKD is autosomal dominant with PKD1 mutations in about 85 percent and PKD2 mutations in the remainder, producing renal and hepatic cyst growth driven by abnormal cholangiocyte proliferation and fluid secretion through dysregulated planar cell polarity signaling.

• Section 22.8: PFIC, BRIC, and Alagille syndrome

  The familial cholestatic syndromes split by GGT pattern and by progression.

Podcast episodes

1. 01

   Hereditary Hemochromatosis

   Episode one of the Inherited Liver Diseases chapter takes hereditary hemochromatosis and reasons from the molecular lesion outward: lose the HFE signal, lose the hepcidin brake, and iron pours in unchecked for decades. The organizing move is that genotype alone is a substrate, not a disease, so diagnosis rests on biochemistry plus genotype, not a positive C282Y result by itself. Iron regulation, the C282Y and H63D alleles, incomplete sex-skewed penetrance, the two-tier diagnostic framework, phlebotomy to a ferritin target, and the reversibility line all run through the episode. The recurring trap is the healthy homozygote with normal iron studies who is surveyed, not treated.

   Read the transcript →
2. 02

   Wilson Disease

   Episode two takes the other metal-handling disease, Wilson, where the toxin is copper and the ATP7B pump fails at two coupled jobs: pushing copper into bile and loading it onto ceruloplasmin. The diagnostic logic is harder because no single test stands alone, so the Leipzig score integrates weighted features and the chelator choice turns on the speed and site of copper movement. Low ceruloplasmin, high urinary copper, the fulminant fingerprint, and trientine-plus-zinc therapy run through the episode. The board traps are the young steatohepatitis patient without metabolic syndrome and the misread fulminant case that costs the transplant window.

   Read the transcript →
3. 03

   A1AT, CF Liver Disease, PCLD, and Cholestatic Syndromes

   Episode three closes the chapter with the four inherited liver diseases beyond the metal pair: alpha-one antitrypsin deficiency, cystic-fibrosis-associated liver disease, polycystic liver disease, and the familial cholestatic syndromes. The unifying move is that mechanism predicts therapy in each one, and each carries a distinct board trap. Alpha-one antitrypsin is the two-organ split where augmentation rescues the lung and does nothing for the liver; CF liver disease is one causal chain treated at three points; polycystic liver disease is synthetic-function-preserved mass effect; and the cholestatic syndromes split by the GGT pattern and cancer risk. Ileal bile acid transporter inhibitors, CFTR modulators, and the MELD exception anchor the modern management.

   Read the transcript →

Key topics

• ·Iron regulation: hepcidin, ferroportin, and HFE
• ·C282Y and H63D genotypes
• ·Non-HFE hemochromatosis and ferroportin disease
• ·Biopsy iron distribution and quantitative thresholds
• ·Incomplete, sex-skewed penetrance
• ·Carrier and homozygote frequencies
• ·Diagnostic criteria and the two-tier framework
• ·Phlebotomy to a ferritin target
• ·Reversibility, cirrhosis, and HCC surveillance
• ·ATP7B and the failed copper exit
• ·Low ceruloplasmin from accelerated degradation
• ·Kayser-Fleischer rings and sunflower cataracts
• ·Hepatic and neuropsychiatric phenotypes
• ·Leipzig diagnostic score and copper tests
• ·The fulminant Wilson fingerprint
• ·Trientine, penicillamine, and zinc
• ·Monitoring with urinary and free copper
• ·Pregnancy and contraception traps
• ·Alpha-one antitrypsin two-organ split
• ·PiZZ, the null genotype, and PAS-diastase-resistant globules
• ·Augmentation and NSAID treatment traps
• ·CF-associated liver disease and CFTR modulators
• ·Polycystic liver disease and the MELD exception
• ·Familial cholestatic syndromes and the GGT split
• ·Cancer risk by mechanism
• ·IBAT inhibitors and pruritus therapy
• ·Alagille syndrome